31st week of 2010 patent applcation highlights part 42 |
Patent application number | Title | Published |
20100196372 | FcgammaRIIB Fusion Proteins and Compositions Thereof - The present invention relates to molecules, preferably soluble (i.e., not membrane bound) polypeptides, most preferably soluble fusion polypeptides comprising the extracellular soluble regions of an FcγR, derivatives and analogs thereof, and nucleic acids encoding same. Molecules of the invention are particularly useful for the treatment, management, or prevention of, or amelioration of one or more symptoms of, an autoimmune disease, especially for ameliorating serum platelet deficiency associated with immune thrombocytopenic purpura. The invention provides methods and compositions for enhancing the therapeutic efficacy of standard, current or experimental therapies for an autoimmune disease by administering a molecule of the invention. | 2010-08-05 |
20100196373 | Intrathecal and Intratumoral Superantigens to Treat Malignant Disease - The presence of tumor nodules in organs often results in serious clinical manifestations and the permeation by cancer cells of sheaths surrounding organs often produces clinical manifestations of pleural effusion, ascites or cerebral edema. The present invention addresses this problem by providing a method for treating minors comprising (a) intratumoral administration of a superantigen and/or (b) intrathecal or intracavitary administration of a superantigen directly into the sheath. Intratumoral superantigen results in significant and sustained reduction of the tumor size. Intrathecal administration produces significant sustained reduction of the fluid accumulation associated with clinical improvement and prolonged survival. Useful superantigen compositions for intrathecal and intratumoral injection include tumoricidally effective homologues, fragments and fusion proteins of native superantigens. Also disclosed is combined therapy that includes intratumoral or intrathecal superantigen compositions in combination with (i) intratumoral low, non-toxic doses of one or more chemotherapeutic drugs or (ii) systemic chemotherapy at reduced and non-toxic doses of chemotherapeutic drugs. | 2010-08-05 |
20100196374 | METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASE - The disclosure relates to OX-2/CD200 (herein referred to as CD200) antibodies and methods of treating autoimmune disease. | 2010-08-05 |
20100196375 | Engineered scFv against Bovine Herpes Virus Type I - The present disclosure describes a single chain variable fragment (scFv) that binds BHV-1 virus comprising a light chain variable region, a linker and a heavy chain variable region. The disclosure also describes nucleic acid molecules encoding the scFv molecules, methods and uses thereof for treating or neutralizing BHV-1 infection and diagnostic methods, agents and kits thereof. | 2010-08-05 |
20100196376 | METHOD FOR REDUCING ALLERGEN-INDUCED AIRWAY HYPERRESPONSIVENESS - Disclosed is a method to reduce airway hyperresponsiveness, such as allergen-induced airway hyperresponsiveness, in a mammal by administering an agent that increases the biological activity of a CGRP receptor. Also disclosed are methods for identifying compounds useful in the present method. | 2010-08-05 |
20100196377 | METHODS OF TREATING, DIAGNOSING OR DETECTING CANCER - The invention provides, inter alia, methods for treating cancer, compositions for treating cancer, and methods and compositions for diagnosing and/or detecting cancer. In particular, the present invention provides compositions and methods for treating, diagnosing and detecting cancers associated with LIV-1 overexpression. | 2010-08-05 |
20100196378 | Removal promoters and inhibitor for apoptosis cells in vivo - The present invention is to provide a removal promoter for apoptotic cells which is capable of immediately removing apoptotic cells in vivo by macrophages, or a removal inhibitor which inhibits the removal of apoptotic cells in vivo by macrophages. A removal promoter for apoptotic cells in vivo containing the milk fat globule-EGF factor 8-L (MFG-E8-L), MFG-E8-L mutant having removal promotion action for apoptotic cells in vivo by macrophages, or preferably a recombinant human or mouse MFG-E8-L, or a recombinant human or mouse MFG-E8-L mutant as an active ingredient is prepared. Such removal promoters specifically bind to apoptotic cells and promote the phagocytosis of apoptotic cells by macrophages by recognizing aminophospholipids such as phosphatidylserine exposed on apoptotic cell surface. On the other hand, a point mutation (D89E) MFG-E8-L mutant is used as a removal inhibitor. | 2010-08-05 |
20100196379 | Group B Streptococcus Polypeptides Nucleic Acids and Therapeutic Compositions and Vaccines Thereof - This invention provides isolated nucleic acids encoding polypeptides comprising amino acid sequences of streptococcal matrix adhesion (Ema) polypeptides. The invention provides nucleic acids encoding Group B streptococcal Ema polypeptides EmaA, EmaB, EmaC, EmaD and EmaE. The present invention provides isolated polypeptides comprising amino acid sequences of Group B streptococcal polypeptides EmaA, EmaB, EmaC, EmaD and EmaE, including analogs, variants, mutants, derivatives and fragments thereof. Ema homologous polypeptides from additional bacterial species, including | 2010-08-05 |
20100196380 | Babesia Subtilisin - Provided is an isolated and purified protein produced by a naturally occurring | 2010-08-05 |
20100196381 | P. ARIASI POLYPEPTIDES, P. PERNICIOSUS POLYPEPTIDES AND METHODS OF USE - Substantially purified salivary | 2010-08-05 |
20100196382 | Nontypeable Haemophilus Influenzae Virulence Factors - The invention relates to a mutation within the sap operon of an avirulent clone of a nontypeable strain of | 2010-08-05 |
20100196383 | Connective Tissue Growth Factor (CTGF-3) - The present invention relates to a novel connective tissue growth factor-3 protein which is a member of the growth factor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human connective tissue growth factor-3 protein. Connective tissue growth factor-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic and therapeutic methods for detecting and treating connective tissue related disorders. | 2010-08-05 |
20100196384 | ANTI-HISTONE H1 MONOCLONAL ANTIBODY AND HYBRIDOMA FOR THE PRODUCTION THEREOF - The present invention discloses anti-histone H1 monoclonal antibodies, hybridomas for the production thereof, and polypeptides, which are useful for suppressing, predicting, or diagnosing transplant rejection in organ transplantation. | 2010-08-05 |
20100196385 | TARGETED BINDING AGENTS DIRECTED TO DLL4 AND USES THEREOF 524 - The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of DLL4 and as diagnostics. | 2010-08-05 |
20100196386 | LIGANDS OF HVEM FOR TREATING HEMATOLOGIC MALIGNANCIES AND AUTOIMMUNE DISEASES - The present invention relates to ligands of HVEM for the treatment of hematologic malignancies, in particular Chronic lymphocytic leukaemia, and for the treatment of autoimmune diseases. | 2010-08-05 |
20100196387 | Disulfide, Sulfide, Sulfoxide, and Sulfone Derivatives of Cyclic Sugars and Uses Thereof - In the present invention there are disclosed new derivatives of dianhydrohexite mononitrate corresponding to formula (I), tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof: | 2010-08-05 |
20100196388 | TARGETED BINDING AGENTS DIRECTED TO SONIC HEDGEHOG HOMOLOG AND USES THEREOF - The invention relates to targeted binding agents against human sonic hedgehog homolog (Shh) and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to Shh. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of Shh and as diagnostics. | 2010-08-05 |
20100196389 | METHODS OF USING CORTICOTROPIN-RELEASING FACTOR FOR THE USE OF THE TREATMENT OF CANCER - Provided herein is a method for treating cancer in a human by administering a high dose of corticotropin-releasing factor (CRF). | 2010-08-05 |
20100196390 | AGONIST ANTI-TRKB MONOCLONAL ANTIBODIES - The present invention provides TrkB agonist antibodies. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to improve nerve function, including treatment of peripheral neuropathies, such as Charcot-Marie-Tooth disease. | 2010-08-05 |
20100196391 | SHIGELLA IPAD PROTEIN AND ITS USE AS A VACCINE AGAINST SHIGELLA INFECTION - The present invention relates to compositions and methods for blocking entry of | 2010-08-05 |
20100196392 | ANTI-SYSTEM ASC AMINO ACID TRANSPORTER 2 (ASCT2) ANTIBODY - An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof. | 2010-08-05 |
20100196393 | MODULATION OF BLOOD BRAIN BARRIER PROTEIN EXPRESSION - There are disclosed agents that inhibit Blood Brain Barrier Proteins (BBBP). Such agents are useful in controlling agents entering and exiting the CNS. This allows for drugs to be more effective and/or allowing side effects of the drugs to be lowered. | 2010-08-05 |
20100196394 | ANTI-CANCER VACCINE COMPOSITION - Combinations of anti-cancer vaccines and inhibitory antibodies to CD223 overcome immune suppression in cancer patients. The vaccines may be isolated antigens, groups of antigens, or whole tumor cells. The inhibitory antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies. | 2010-08-05 |
20100196395 | ANTI-IGF ANTIBODIES - Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer. | 2010-08-05 |
20100196396 | COMPOSITIONS AND METHODS FOR MODULATING GHRELIN-MEDIATED CONDITIONS - In certain aspects, the preproghrelin gene, but not the ghrelin receptor (GHS-R1a) is required for normal integration of thermoregulation and sleep in mice. Particular aspects provide methods for modulation of thermoregulation and other ghrelin-mediated conditions (e.g., reduction of appetite or food intake, reduction of body weight or treatment of obesity, reduction of body temperature or induction of hypothermia, etc.), comprising administration of an inhibitor of ghrelin expression, and including, e.g., siRNA inhibition for treatment of obesity and for modulation of thermoregulation (e.g., induction of hypothermia in surgical settings benefiting from same). Additionally provided are methods for reducing body temperature or induction of hypothermia, comprising administration to a mammalian subject in need thereof an amount of an anti-obestatin antibody agent sufficient to reduce body temperature or induce hypothermia. Further methods comprise administration of a ghrelin peptide antagonist. | 2010-08-05 |
20100196397 | Five-helix protein - Five-Helix protein, which comprises the three N-helices and at least two, but not three, of the three C-helices of the trimer-of-hairpin structure of HIV gp41, separated by linkers, such as amino acid residue linkers, is disclosed. Six-Helix protein, which includes the three N-helices and the three C-helices of the trimer-of-hairpin structure of HIV gp41, separated by linkers, is also disclosed. | 2010-08-05 |
20100196398 | TARGETED BINDING AGENTS DIRECTED TO CD105 AND USES THEREOF - The invention relates to targeted binding agents against CD105 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to CD105. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of CD105 and as diagnostics. | 2010-08-05 |
20100196399 | LDL Receptor-Related Proteins 1 and 2 and Treatment of Bone or Cartilage Conditions - LDL receptor-related proteins 1 and 2 (LRP-1 and LRP-2) and interaction between lactoferrin and LRP-1, LRP-2, or p42/44 MAP kinase in diagnosis and treatment of disorders such as bone or cartilage disorders. Also disclosed are methods of screening for related therapeutic compounds. | 2010-08-05 |
20100196400 | GENETIC POLYMORPHISMS ASSOCIATED WITH ALZHEIMER'S DISEASE, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with Alzheimer's Disease. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 2010-08-05 |
20100196401 | USE OF RAPAMYCIN TO INHIBIT IMMUNE RESPONSE AND INDUCE TOLERANCE TO GENE THERAPY VECTOR AND ENCODED TRANSGENE PRODUCTS - Disclosed are methods for transient co-administration of rapamycin together with a gene therapy vector encoding a transgene. The present invention is directed to inhibiting the immune response of a host to the administered gene therapy vector and encoded trans gene product, thus allowing persistent trans gene expression and repeated administration of the gene therapy product to the host. The present invention is also of relevance in genetic disease patients that mount immune responses to protein replacement therapies in which case the present invention provides for transient co-administration of rapamycin together with protein replacement therapy. In a further aspect of the invention, co-administration of rapamycin could inhibit a secondary immune response in a host that has been pre-immunized with the gene therapy vector or pre-immunized with the protein product encoded by the transgene. | 2010-08-05 |
20100196402 | Method for Predicting the Response of a Patient to Treatment with an Anti-TNF Alpha Antibody - The present invention relates to a method for predicting the response of a patient to treatment with an anti-TNFα therapy, in particular an anti-TNFα antibody, the method comprising: (a) providing an in vitro sample of T cells from the patient; (b) exposing said T cells to an anti-TNFα therapy; and (c) determining whether regulatory T cells are induced in said sample of T cells wherein the induction of regulatory T cells indicates that the patient is likely to respond to treatment with said anti-TNFα therapy. | 2010-08-05 |
20100196403 | ANTIBODY CONJUGATES FOR CIRCUMVENTING MULTI-DRUG RESISTANCE - Conjugates of a cell permeability moiety coupled to an antibody against an intracellular epitope of a multi drug resistance (MDR) protein are provided. Also provided are pharmaceutical compositions that include these conjugates and methods for their use in preventing and inhibiting multi drug resistance to therapeutic agents, particularly to chemotherapeutic agents. | 2010-08-05 |
20100196404 | METHODS OF USE OF THE TACI/TACI-L INTERACTION - The invention discloses a novel interaction between a TNF receptor (TACI) and its interacting ligand (TACI-L). Also disclosed are methods of screening candidate molecules to determine potential antagonists and agonists of the TACI/TACI-L interaction. The use of the antagonists and agonists as therapeutics to treat autoimmune diseases, inflammation, and to inhibit graft vs. host rejections is further disclosed. | 2010-08-05 |
20100196405 | GLP-1 Fc FUSION PROTEIN FORMULATION - The invention provides a stable solution formulation comprising a therapeutically effective amount of a GLP-1-Fc fusion protein at about pH 6.5 in citrate buffer with polysorbate-80 and mannitol. The formulation is useful in treating diabetes and obesity as well as a variety of other conditions or disorders. | 2010-08-05 |
20100196406 | AGENTS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND METHODS OF USING SAME - A method of treating an autoimmune disease such as Multiple Sclerosis is disclosed. The method comprises administering to a subject a therapeutically effective amount of CXCL11. Polypeptides and pharmaceutical compositions for treating same are also disclosed. | 2010-08-05 |
20100196407 | TICK GALECTIN - A novel galectin, a polynucleotide encoding the same, a vector and a transformant comprising the polynucleotide, an antibody against the galectin, and a screening method for screening a substance capable of modifying the galectin, are disclosed. According to the galectin, polynucleotide, or vector, it is possible, for example, to exterminate ticks, or to treat or prevent tick-borne infections such as rickettsiosis, filariasis, Q fever, African recurrent fever, or viral encephalitis. | 2010-08-05 |
20100196408 | METASTATIC COLORECTAL CANCER VACCINE - The invention relates to prophylactic and therapeutic vaccines for protecting individuals against metastatic colorectal cancer and for treating individuals who are suffering from metastatic colorectal cancer. | 2010-08-05 |
20100196409 | BASB006 POLYPEPTIDES FROM NEISSERIA MENINGITIDIS AND IMMUNOGENIC COMPOSITIONS THEREOF - The invention provides BASB006 polypeptides and polynucleotides encoding BASB006 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. | 2010-08-05 |
20100196410 | Streptococcus pneumoniae Antigens and Vaccines - The present invention relates to novel vaccines for the prevention or attenuation of infection by | 2010-08-05 |
20100196411 | Yeast-Based Vaccine for Inducing an Immune Response - The invention provided herein relates to vaccines that can be tailored to achieve a desired immune response. Some compositions provided herein are used for preferentially eliciting a humoral immune response while other compositions are useful for preferentially eliciting a cell-mediated response. Combinations of vaccine compositions are also useful for eliciting both types of responses and/or for modulating the type of immune response elicited. The invention also provides methods for eliciting an immune response in an individual by administering the compositions disclosed herein. These immune responses are useful for protecting an individual from various types of diseases, infections, and undesirable conditions. | 2010-08-05 |
20100196412 | HOMOGENEOUS VACCINE COMPOSITION FOR THE TUMOR TREATMENT AND ITS OBTAINING METHOD - The present invention relates to the biotechnological field and particularly to the human health. More particularly, the present invention relates to a vaccine composition for therapeutic use in cancer patients. | 2010-08-05 |
20100196413 | Use of Yeast Flakes for Treating and/or Preventing Hyperinsulinemia - The invention relates to the use of yeast flakes for preparing a pharmaceutical composition for treating and/or preventing hyperinsulinemia. | 2010-08-05 |
20100196414 | Silver Ionized Plant Extraction Liquid and Use Thereof - The present invention relates to silver-ionized plant extraction liquid and the use thereof. Particularly, there are provided herein a silver-ionized liquid extraction liquid prepared by ionizing silver in a plant extraction liquid used as an electrolyte and an antimicrobial composition comprising the same. | 2010-08-05 |
20100196415 | PROCESS FOR PURIFYING GUAR - The present invention relates to processes for purifying guar comprising combining borate and guar in an aqueous solution and treating the aqueous solution with an organic solvent to induce precipitation of purified guar. Another embodiment of the present invention is directed to ophthalmic formulations comprising purified guar produced by the processes described. | 2010-08-05 |
20100196416 | Vaccine - A typhoid vaccine using heat shock protein (Hsp) of | 2010-08-05 |
20100196417 | COMPOSITIONS COMPRISING A B SUBUNIT OF SHIGA TOXIN AND A MEANS STIMULATING NKT CELLS - The present invention relates to a composition comprising a) a B subunit of Shiga toxin or a functional equivalent thereof which is able to bind the Gb3 receptor, complexed with an antigen and b) at least one ligand of CDI capable of stimulating NK T cells; and to a pharmaceutical composition and a medicament comprising said composition. | 2010-08-05 |
20100196418 | UNIVERSAL CARRIER FOR TARGETING MOLECULES TO Gb3 RECEPTOR EXPRESSING CELLS - The present invention concerns an universal polypeptidic carrier for targeting directly or indirectly a molecule to Gb3 receptor expressing cells and having the following formula STxB-Z(n)-Cys, wherein:
| 2010-08-05 |
20100196419 | ENHANCEMENT OF GLYCOPROTEIN INCORPORATION INTO VIRUS-LIKE PARTICLES - Embodiments of the present disclosure encompasses virus-like particles, methods of making virus-like particles, including expression vectors, wherein the virus-like particles may comprise enhanced levels of capsid-bound a chimeric HN-Env polypeptide compared to VLPs derived from unmodified HIV-env polypeptides. Embodiments of the virus-like particle may have Env-specific epitopes exposed on the outer surface thereof. In one embodiment, the Env-specific epitopes exposed on the outer surface of the virus-like particle may specifically bind with an anti-HIV-Env specific antibody. Embodiments of the disclosure further includes methods of generating an antibody specific to an epitope of an HIV-Env polypeptide, comprising delivering to an animal or a human an effective amount of a suspension of virus-like particles comprising a chimeric HIV-Eny polypeptide, thereby inducing the formation of an antibody specific to an epitope of an HIV-1 eny polypeptide. | 2010-08-05 |
20100196420 | IMMUNOGENIC COMPOSITIONS, VACCINES AND DIAGNOSTICS BASED ON CANINE DISTEMPER VIRUSES CIRCULATING IN NORTH AMERICAN DOGS - Immunogenic compositions and broad-spectrum vaccines containing newly identified isolates of canine distemper virus (CDV) collected from a geographic area are provided. The newly identified isolates exhibit attributes of both European wildlife lineage CDV and one or both of Arctic and American-2 lineage CDV. Therefore, the vaccines are broadly protective against infection with European wildlife lineage CDV and either Arctic lineage CDV or American-2 lineage CDV, or both Arctic and American-2 lineage CDV. | 2010-08-05 |
20100196421 | GENETICALLY ENGINEERED CLOSTRIDIAL GENES, PROTEINS ENCODED BY THE ENGINEERED GENES, AND USES THEREOF - The present invention relates to an isolated Clostridial neurotoxin propeptide having a light chain region, a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond, and an intermediate region connecting the light and heavy chain regions. An isolated nucleic acid molecule encoding a Clostridial neurotoxin propeptide is also disclosed. Also disclosed is an isolated, physiologically active Clostridial neurotoxin produced by cleaving a Clostridial neurotoxin propeptide, a vaccine or antidote thereof, and methods of immunizing against or treating for toxic effects of Clostridial neurotoxins. Methods of expressing recombinant physiologically active Clostridial neurotoxins are also disclosed. Also disclosed is a chimeric protein having a heavy chain region of a Clostridial neurotoxin and a protein with therapeutic functionality. A treatment method is also disclosed. | 2010-08-05 |
20100196422 | NOVEL POLYPEPTIDES FOR ISOLATING IN VITRO AND PREVENTING STAPHYLOCCOCAL INFECTIONS ON JOINT PROSTHESES AND OTHER IMPLANTED FOREIGN MATERIALS - The invention concerns novel polypeptides, or parts or variants of the novel polypeptides, the use of sequences encoding the polypeptides and the use of antibodies directed against the polypeptides in the field of in vitro diagnosis of a | 2010-08-05 |
20100196423 | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases - The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. | 2010-08-05 |
20100196424 | STABILIZATION OF LONG CHAIN POLYUNSATURATED OILS - Compositions that include an oxidizable fatty acid-containing oil and wax capable of limiting oxidation of the oil are disclosed. Also disclosed are compositions that include an ingestible fatty acid-containing oil and an ingestible wax. Polyunsaturated fatty acid-containing oils may be stabilized by mixing the oil with a melted wax capable of limiting oxidation of the oil, and allowing the mixture to cool. | 2010-08-05 |
20100196425 | OROS PUSH-STICK FOR CONTROLLED DELIVERY OF ACTIVE AGENTS - A sustained release dosage form is provided comprising a pharmaceutically active agent and pharmaceutically acceptable salts thereof and adapted to release as an erodible solid over a prolonged period of time, wherein the dosage form provides burst release of the pharmaceutically active agent without the use of an immediate release drug coating. The dosage form is able to deliver high doses of poorly soluble or slowly dissolving active agents at a controlled rate. Methods of using the dosage forms to treat disease or conditions in human patients are also disclosed. | 2010-08-05 |
20100196426 | USE OF MICROVESICLES IN DIAGNOSIS AND PROGNOSIS OF MEDICAL DISEASES AND CONDITIONS - The presently disclosed subject matter is directed to methods of aiding diagnosis, prognosis, monitoring and evaluation of a disease or other medical condition in a subject by detecting a biomarker in microvesicles isolated from a biological sample from the subject. | 2010-08-05 |
20100196427 | DELAYED-RELEASE GLUCOCORTICOID TREATMENT OF RHEUMATOID ARTHRITIS BY IMPROVING SIGNS AND SYMPTOMS, SHOWING MAJOR OR COMPLETE CLINICAL RESPONSE AND BY PREVENTING FROM JOINT DAMAGE - The present invention refers to the treatment of a patient suffering from rheumatoid arthritis by showing a reduction in signs and symptoms, a major or complete clinical response (remission) or even prevention of structural damages to the joints by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof. | 2010-08-05 |
20100196428 | METHOD FOR PRODUCING COSMETIC PREPARATIONS - The present invention relates to a method for producing cosmetic preparations comprising metal oxide, where the reaction mixture which forms during the production of the particulate metal oxide is incorporated into the cosmetic preparations essentially without further work-up. | 2010-08-05 |
20100196429 | Oil-In-Water Emulsion Composition And Method For Producing The Same - The present invention provides: an oil-in-water emulsion composition, into which an oil-soluble drug is stably incorporated and which is excellent in feeling during use; and a method for producing the aforementioned composition, which does not require complicated operations. An oil-in-water emulsion composition comprising; (A) a polyoxyethylene phytosterol, (B) a glycerin fatty acid diester, (C) a polyoxyethylene-polyoxypropylene random copolymer dialkyl ether, (D) an oil-soluble drug, (E) oil, and (F) water; wherein a layered gel structure composed of the components (A) and (B) is present in an emulsion particle in the emulsion composition. | 2010-08-05 |
20100196430 | Controlled-released agricultural chemical formulation - An object of the present invention is to provide an agricultural chemical formulation which is able to control release of an agricultural chemical active ingredient. This agricultural chemical formulation includes a composition, containing an agricultural chemical active ingredient, styrene-maleic anhydride copolymer or mixture of styrene-maleic anhydride copolymer and polymer having repeating units derived from rosin or derivative thereof or salicylic acid or derivative thereof, and a release controller (a water-soluble polymer, a hydrophobically-treated silicon oxide, or a surfactant), forming a compatible state or matrix. | 2010-08-05 |
20100196431 | GRANULE COATED WITH URETHANE RESIN - A coated granule is obtained by coating a bioactive substance-containing granule with a urethane resin obtained by reaction of an aromatic diisocyanate with a polyol mixture containing a polyesterpolyol and a C2-C8 polymethylene glycol, wherein the molar ratio of the polyesterpolyol to the polymethylene glycol is 1:20 to 20:1. The granule is capable of controlling elution of the bioactive substance appropriately, and the urethane resin forming the coating film shows degradability in soil. | 2010-08-05 |
20100196432 | BIOPOLYMER STRUCTURES - The invention described herein relates to biopolymer structures. The biopolymer structures are spatially organized from the nanometer to centimeter length scales and incorporate functionally active cells. Applications of the biopolymer structures include use with stem cells. | 2010-08-05 |
20100196433 | PREVASCULARIZED DEVICES AND RELATED METHODS - The present invention provides an implantable devices for providing a biologically active agent to a subject in need thereof, the device comprising a microvessel construct in contact with a biocompatible, semi-permeable pouch, the pouch encapsulating a cell or cells capable of producing the biologically active agent. The present invention also provides methods for treating or preventing a disorder in a subject using the implantable device. The present invention also provides specific methods for treating or preventing diabetes in a subject comprising implanting in the subject an immunoisolation device comprising a microvessel construct in contact with a biocompatible, semi-permeable pouch, the pouch encapsulating a cell or cells capable of producing a therapeutically effective amount of insulin. Methods for vascularizing and revascularizing tissue, including engineered tissue, are also provided. | 2010-08-05 |
20100196434 | COMBINED FIBNRINOLYTIC AND ANTIMICROBIAL CATHETHER AND USES THETHEROF - Implantable catheters are provided which comprise an antimicrobial agent incorporated in a coating or bulk distributed, in combination with a fibrinolytic agent incorporated in a top coating. | 2010-08-05 |
20100196435 | MATERIALS AND METHODS FOR DELIVERING COMPOSITIONS TO SELECTED TISSUES - This invention relates to devices, systems and methods for delivering preprogrammed quantities of an active ingredient to a biological system over time without the need for external power or electronics. | 2010-08-05 |
20100196436 | IMPLANTS CONTAINING DISULFIRAM AND AN ANTI-INFLAMMATORY AGENT - The present invention provides an implantable composition which contains disulfiram, an anti-inflammatory agent, and optionally a pharmaceutically acceptable carrier. Methods of making the implants, and methods of using the implants to treat alcoholism and opioid dependency are also disclosed. | 2010-08-05 |
20100196437 | MEDICAL DEVICES HAVING A SURFACE INCLUDING A BIOLOGICALLY ACTIVE AGENT THEREIN - The present invention provides a medical device, and methods of preparing and using a medical device. The medical device has a surface including a biologically active agent therein. The methods are particularly useful for preparing, for example, coated stents having a biologically active agent within the coating. | 2010-08-05 |
20100196438 | METHODS INCLUDING MEDICAL DEVICES HAVING A SURFACE INCLUDING A BIOLOGICALLY ACTIVE AGENT THEREIN - The present invention provides a medical device, and methods of preparing and using a medical device. The medical device has a surface including a biologically active agent therein. The methods are particularly useful for preparing, for example, coated stents having a biologically active agent within the coating. | 2010-08-05 |
20100196439 | Angiogenesis Mechanism and Method, and Implantable Device - Various methods and devices are provided for providing therapy to a living body. In one embodiment, an implanted permeable container has living cells provided therein, and various nutrients and/or agents are provided into the container to promote cell life. | 2010-08-05 |
20100196440 | Implant Material - The present relates to the field of dental and bone surgery. In particular, the invention relates to fibrous pharmaceutical compositions; fibrous webs, yarns and woven fabrics of such pharmaceutical compositions; to implant material essentially consisting of fibrous pharmaceutical compositions; to the manufacturing and use of such fibers/webs/implant materials. | 2010-08-05 |
20100196441 | USES OF IMMUNOLOGICALLY MODIFIED SCAFFOLD FOR TISSUE PREVASCULARIZATION CELL TRANSPLANTATION - This invention provides method of making and using of a porous 3 dimensional cyclic RGD peptide-modified alginate scaffold that can be loaded with different cell types and/or growth factors for implantation at sites of tissue damage to promote tissue regeneration. The cyclic RGD peptide promotes vascular formation of the host tissue, cell binding and survival of seeded cells. Scaffolds with growth factors but without cells can also be implanted to create a vascular bed in which cells are transplanted at a later time point. | 2010-08-05 |
20100196442 | METHODS FOR TREATING OPEN WOUNDS - A method for treating an open wound, such as a surgical wound, may include preparing a first composition including a platelet poor plasma (PPP), and preparing a second composition including a platelet rich plasma (PRP). A layer of the first composition may be applied within the open wound, and a layer of the second composition may be applied within the open wound over the layer of the first composition. | 2010-08-05 |
20100196443 | USE OF CORDYCEPS SPECIES OR EXTRACT THEREOF IN THE EGG PRODUCTION - A dietary supplement or animal feed includes at least one | 2010-08-05 |
20100196444 | DEVICES WITH CELLS CULTURED ON FLEXIBLE SUPPORTS - Methods and compositions provide suitable support material for culturing cells with a desirable metabolic activity. For example, keratinocytes directly grown on flexible supports show metabolic activity. Wound healing methods and compositions using the cells grown on flexible supports, wherein the cells exhibit increased metabolic activity are disclosed. | 2010-08-05 |
20100196445 | SYSTEMS AND METHODS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS - The invention provides methods and devices for the delivery of therapeutic or biologically active agents to tissue, for example by facilitating the transport of said agents through the skin of a human or animal. Therapeutic agents include various botulinum neurotoxin (BoNT) and other biologically active agents, which can be delivered across the skin and into the dermis using multiple strategies including microneedle drug delivery, transport moieties, or penetration enhancers such as extracellular matrix-digestive enzymes. | 2010-08-05 |
20100196446 | Drug delivery and substance transfer facilitated by nano-enhanced device having aligned carbon nanotubes protruding from device surface - The present invention relates to a nano-enhanced device for substance transfer between the device and a tissue. The device comprises a substrate with substantially aligned carbon nanotubes anchored within the substrate, and with at least one end of the carbon nanotubes protruding from the substrate. The protruding nanotube ends may be coated with a drug for delivery of the drug into body tissue. The present invention may be incorporated into an angioplasty catheter balloon or into a patch that is worn on the skin. The carbon nanotubes can be grouped in clusters to effectively form nano-needles which can transfer fluid to or from the subdermal tissue. The nano-needles can be used in conjunction with a sensor to ascertain body fluid information such as pH, glucose level, etc. | 2010-08-05 |
20100196447 | SILK BIOMATERIALS AND METHODS OF USE THEREOF - The present invention provides an all-aqueous process and composition for production of silk biomaterials, e.g., fibers, films, foams and mats. In the process, at least one biocompatible polymer, such as poly(ethylene oxide) (PEO) (a well-documented biocompatible material), was blended with the silk protein prior to processing e.g., electrospinning. We discovered that this step avoids problems associated with conformational transitions of fibroin during solubilization and reprocessing from aqueous solution which lead to embrittled materials. Moreover, the process avoids the use of organic solvents that can pose problems when the processed biomaterials are exposed to cells in vitro or in vivo. | 2010-08-05 |
20100196448 | WOUND HEALING DRESSING AND METHODS OF MANUFACTURING THE SAME - Disclosed are a hydrogel dressing for covering or treating a wound and a method for preparing the same. The hydrogel dressing includes a matrix structure of a cross-linked mixture, and an elastic sheet coated with an elementary metal or ionic metal embodied in the matrix structure. The mixture comprises a hydrophilic polymer, about 0.5 to about 5 wt % of a photocatalyst agent and at least 80 wt % of water based on the total weight of the mixture. | 2010-08-05 |
20100196449 | SYSTEM AND METHOD TO IMPROVE SENSORY FUNCTION - A system and method to improve sensory functions in the hand or foot by dermal topical application of a local anaesthetic substance to adjacent skin areas, using a tailored application device or kit specially designed to fit the size and anatomical shape of the body part which is to be anaesthetised. The concept is to block sensory input from the anaesthetised skin area hereby inducing a functional reorganisation in sensory brain cortex resulting in enhanced sensory functions in body parts adjacent to the anaesthetised area with focus on the hand and sole of the foot. | 2010-08-05 |
20100196450 | TARGETING PAX2 FOR THE INDUCTION OF DEFBI-MEDIATED TUMOR IMMUNITY AND CANCER THERAPY - Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject. | 2010-08-05 |
20100196451 | Vaccines Containing Non-Live Antigenic Vectors - The present invention provides a vaccine composition comprising a non-live vector which targets the MHC class I pathway derived from a bacterial toxin or an immunologically functional derivative thereof but excluding those which bind the Gb3 receptor complexed with at least one first antigen and further comprising at least one second antigen (which may be the same or different as the first antigen) and an adjuvant. | 2010-08-05 |
20100196453 | BIPHASIC LIPID-VESICLE COMPOSITION AND METHOD FOR TREATING CERVICAL DYSPLASIA BY INTRAVAGINAL DELIVERY - A biphasic lipid vesicle composition for treating cervical displasia by intravaginal delivery. The composition includes a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and L-methionine, the composition having an interferon alpha-2b specific activity of between about 1-10 MIU (million international units) per gram composition, and between 0.01 to 0.5 weight percent L-methionine. In the treatment method, the composition is administered at a dose of between about 1-20 MIU interferon alpha-2b, and this dose is administered at least 3 days/week, for a period of at least 4 weeks. | 2010-08-05 |
20100196454 | DRESSING FORMULATIONS TO PREVENT AND REDUCE SCARRING - Provided herein is a scar dressing formulation comprising a blend of a high molecular weight silicone elastomer crosspolymer and a silicone oil, wherein said silicone elastomer crosspolymer is in a volatile fluid. The formulation has a soft, silky feel without being greasy and dries quickly to form a durable, flexible scar dressing. | 2010-08-05 |
20100196455 | Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof - The present invention relates, in part, to a composition comprising a multicationic drug and an organic multianion. In some embodiments, the multicationic drug is enclosed within a carrier. In some embodiments, the carrier is a liposome. In some embodiments, the multicationic drug and organic multianion are enclosed within a carrier, while in other embodiments, the multicationic drug is enclosed within the carrier and the organic multianion is outside the carrier. The present invention also relates, in part, to a method of treating a subject for pulmonary distress comprising administering to a subject in need thereof the aforementioned composition. | 2010-08-05 |
20100196456 | EMULSION PRECONCENTRATES AND MICELLAR FORMULATIONS CONTAINING WOOD RESINS - The invention relates to micelles and emulsion preconcentrates comprising i) one or more active ingredients and ii) wood resin, optionally in combination with gum arabic, and iii) optionally additional adjuvants; products containing said micelles and/or emulsion preconcentrates, method for the production of micelles, emulsion preconcentrates, and products. | 2010-08-05 |
20100196458 | MODIFIED CYTOKINES FOR USE IN CANCER THERAPY - Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents. | 2010-08-05 |
20100196459 | THERAPEUTIC FORMULATIONS CONTAINING VENOM OR VENOM ANTI-SERUM EITHER ALONE OR IN COMBINATION FOR THE THERAPEUTIC PROPHYLAXIS AND THERAPY OF NEOPLASMS - A method of treating a mammal prophylactically to prevent neoplastic development comprises administering to the mammal a therapeutic vaccine comprising venom and at least one adjuvant. The method optionally further comprises administering to the mammal at least one other therapeutically effective agent, e.g., an anti-inflammatory agent. | 2010-08-05 |
20100196460 | Integrated Photoactive Agents for Real-Time Monitoring of Hemostasis - The present invention discloses a number of photoactive compounds designed to bind and inhibit serine proteases. Compounds disclosed herein may be utilized in a number of appropriate medical diagnostic and/or therapeutic procedures such as the monitoring of hemostasis, imaging and/or treatment of vulnerable plaques, and/or tumor imaging and/or treatment. | 2010-08-05 |
20100196461 | RESUSCITATION FLUID - A method for treating conditions related to lack of blood supply with a resuscitation fluid is disclosed. The resuscitation fluid contains a lipophilic component and a polar liquid carrier. The lipophilic component forms an emulsion with the polar liquid carrier. The resuscitation fluid can be used to increase the blood pressure and to carry oxygen and other lipophilic gases to tissues. The resuscitation fluid can also be used for preserving the biological integrity of donor organs for transplantation. | 2010-08-05 |
20100196462 | Method for Manufacturing a Pharmaceutical Form of Oseltamivir Phosphate - The invention relates to a method for manufacturing a pharmaceutical form of oseltamivir phosphate, characterized by including the following steps:
| 2010-08-05 |
20100196463 | METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS - The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment. | 2010-08-05 |
20100196464 | ORLISTAT PHARMACEUTICAL FORMULATIONS - Solid pharmaceutical formulations are prepared using compositions comprising orlistat and having average particle sizes less than about 250 μm. | 2010-08-05 |
20100196465 | STABLE PHARMACEUTICAL COMPOSITION OF A WATER-SOLUBLE VINORELBINE SALT - A stable pharmaceutical composition comprising a water-soluble vinorelbine salt and at least one diluent and one lubricant, characterized in that it appears in a solid form intended for oral administration. The water-soluble vinorelbine salt is advantageously vinorelbine ditartrate. The pharmaceutical composition advantageously appears as a gelatin capsule or tablet. | 2010-08-05 |
20100196466 | DRUG DELIVERY SYSTEM - A novel encapsulated product is provided and includes: at least one pharmaceutical; at least one compressible material; and at least one tableting material; wherein the encapsulated product is in the form of a caplet having a diameter of from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters. A method for preparing the encapsulated product is also provided. | 2010-08-05 |
20100196467 | THERAPEUTIC COMBINATION OF AMLODIPINE AND BENAZEPRIL/BENAZEPRILAT - The present invention especially relates to the use of a combination comprising | 2010-08-05 |
20100196468 | STABLE PHARMACEUTICAL COMPOSITION COMPRISING A HYDROSOLUBLE VINFLUNINE SALT - Stable pharmaceutical composition consisting of a hydrosoluble vinflunine salt and at least one diluent and one lubricant, said composition being in the form of a solid intended for oral administration. The hydrosoluble vinflunine salt is preferably Vinflunine ditartrate. The pharmaceutical composition is advantageously in the form of a capsule or tablet. The invention also concerns a method of treating cancer pathology comprising the oral administration of the pharmaceutical composition of the invention. | 2010-08-05 |
20100196469 | Pharmaceutical Formulation containing an HMG-COA Reductase Inhibitor and method for the preparation thereof - The present invention relates to the formulation of solid dosage forms comprising a therapeutically effective amount of an HMG-CoA reductase inhibitor, and especially Atorvastatin or Fluvastatin or salts thereof, in combination with colloidal clay such as Attapulgite, and a process for the preparation thereof by direct compression. | 2010-08-05 |
20100196470 | DEVICE AND METHOD FOR REDUCING CALORIE INTAKE - Devices and methods for substantially reducing the caloric efficiency of the digestive tract by capturing food being digested in the stomach | 2010-08-05 |
20100196471 | NOVEL TABLET DOSAGE FORM - The present invention relates to novel tablet dosage forms and methods of preparing these forms, which can be used for different classes of pharmaceutical active ingredients posing stability issues in a single unit system. The dosage form includes a first layer, which includes a tablet of one or more active pharmaceutical ingredients, which is inlayed in the first layer along with other pharmaceutically acceptable excipients, and a second layer that includes one or more active pharmaceutical ingredients optionally with other pharmaceutically acceptable excipients. | 2010-08-05 |
20100196472 | MODIFIED RELEASE COMPOSITIONS OF MILNACIPRAN - A milnacipran formulation that provides delayed and extended release of milnacipran has been developed. The formulation comprises milnacipran or a salt thereof; an extended release excipient, and a delayed release excipient. The formulation provides, upon administration to a human subject, a T | 2010-08-05 |
20100196473 | Pharmaceutical Composition Containing 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol with Delayed Active Ingredient Release - Pharmaceutical compositions with delayed release which contains 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol or a pharmaceutically acceptable salt thereof in a matrix with delayed active ingredient release, wherein the matrix contains 1 to 80 wt. % of one or more hydrophilic or hydrophobic polymers as pharmaceutically acceptable matrix formers and exhibits the following in vitro release rate: 3-35 wt. % (relative to 100 wt. % of active ingredient) of 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol released after 0.5 hours, 5-50 wt. % after 1 hour, 10-75 wt. % after 2 hours, 15-82 wt. % after 3 hours, 30-97 wt. % after 6 hours, more than 50 wt. % after 12 hours, more than 70 wt. % after 18 hours, and more than 80 wt. % after 24 hours. | 2010-08-05 |